NCT06604533 Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer
| NCT ID | NCT06604533 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Australasian Gastro-Intestinal Trials Group |
| Condition | Abdominal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-07-07 |
| Primary Completion | 2030-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-07-07 with a primary completion date of 2030-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to investigate the effect of MRI-guided adaptive stereotactic radiotherapy on local control, survival, and toxicity in the treatment of oligometastatic cancer to the abdomen.
Eligibility Criteria
Inclusion Criteria: * Aged 18 years or older * Patients with diagnosis of oligometastatic disease from primary colorectal, upper gastrointestinal (e.g. gastric, oesophagus, pancreatic), breast, non-small cell lung, renal cell, or gynaecological malignancy. Oligometastatic disease with controlled primary disease\* and maximum total of 5 metastatic lesions in a maximum of 2 different organ systems in any of the following sites: 1. Liver 2. Adrenal 3. Abdomino-pelvic lymph node 4. Other abdominal site e.g. pancreatic, renal. 5. Other pelvic site 6. Bony or lung is allowed only if in conjunction with an abdominal site above * De novo or metachronous oligometastatic disease where the original tumour site has been treated with curative intent. * Controlled primary disease in metachronous oligometastastic disease defined as at least 3 months since original tumour treated with curative intent and no progression at primary site * Controlled primary disease in de novo oligometastatic disease defined as primary tumour site treated with curative intent and no progression at primary site * Oligometastatic disease: Histological confirmation of primary malignancy (histological confirmation of metastasis is not mandatory but should be performed in any situation where there is any diagnostic uncertainty). * All oligometastatic sites treatable with SABR. OR * Patients with oligo-progressive / oligo-persistent disease in maximum total of 2 oligo-progressive abdominal metastases and in a maximum 2 different organ systems * Visible imaging defined targets and suitable for treatment with SABR * Childs Pugh A to B7 (in case of liver treatment) * ECOG 0 -2 * Patient consented Exclusion Criteria: * Contra-indication to MRI * Previous high dose radiotherapy to a site requiring stereotactic treatment (including SIRTEX). Further SABR treatment of lesions previously treated with SABR or high dose radiotherapy is not permitted in this trial. * Substantial overlap with a previously treated high dose (definitive or stereotactic dose) radiation volume. * Primary prostate cancer, carcinoid tumours, germ cell tumours, lymphoma, small cell tumours * Pregnant women * Complete response of metastatic disease to systemic therapy (i.e. no target for SABR) * Competing medical co-morbidity with a more limited prognosis than the cancer diagnosis
Contact & Investigator
Trang Pham
STUDY CHAIR
South Western Sydney LHD
Frequently Asked Questions
Who can join the NCT06604533 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Abdominal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06604533 currently recruiting?
Yes, NCT06604533 is actively recruiting participants. Contact the research team at sukanya@gicancer.org.au for enrollment information.
Where is the NCT06604533 trial being conducted?
This trial is being conducted at Darlinghurst, Australia, Melbourne, Australia.
Who is sponsoring the NCT06604533 clinical trial?
NCT06604533 is sponsored by Australasian Gastro-Intestinal Trials Group. The principal investigator is Trang Pham at South Western Sydney LHD. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.